CRA expert retained in licensing dispute regarding "fair market value" of pharmaceutical product rights

CRA was retained in an arbitration licensing dispute that included the proper “fair market value” of rights exchanged and whether the transfer of such rights would trigger a “payment” under the terms of the agreement. CRA reviewed Claimant’s damages claims and provided opinions as to whether it properly constituted an estimate of “fair market value.”

Meet Our Team